<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356772</url>
  </required_header>
  <id_info>
    <org_study_id>LT1225-PI4-11/02(F)</org_study_id>
    <nct_id>NCT00356772</nct_id>
  </id_info>
  <brief_title>Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers</brief_title>
  <official_title>Comparison of Azithromycin Level in Tears and in Conjunctiva After Repeated Instillations of T1225 1.5% Eye Drops or After a Single Per Os Administration of Zithromax® (Azithromycin 1g), in 36 Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <brief_summary>
    <textblock>
      To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment&#xD;
      initiation.&#xD;
&#xD;
      To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study was to compare azithromycin tear and conjunctival ocular&#xD;
      concentrations after one instillation of T1225 1.5% eye drops, twice a day during one day&#xD;
      versus one instillation of T1225 1.5% eye drops, twice a day during 3 days versus an oral&#xD;
      single dose of 1g azithromycin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date>March 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Azithromycin Ocular Conjunctiva Concentrations on Days 7 and 14.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Azithromycin Tear Concentrations on Day 7.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
  </secondary_outcome>
  <condition>Eye Infections, Bacterial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Healthy volunteers;&#xD;
&#xD;
          -  Registered in the national register of healthy volunteers;&#xD;
&#xD;
          -  Male or female aged from 18 to 45 years old;&#xD;
&#xD;
          -  Able to understand the study instructions;&#xD;
&#xD;
          -  Likely to comply with the study schedule and treatment;&#xD;
&#xD;
          -  Normal subjective ocular symptoms, Schirmer test &gt; 10 mm in 5 min and corrected visual&#xD;
             acuity &gt;= 6/10 in both eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular trauma, infection or inflammation within the last 3 months;&#xD;
&#xD;
          -  Blepharitis;&#xD;
&#xD;
          -  Conjunctival hyperaemia (score &gt;= 2);&#xD;
&#xD;
          -  Fluorescein-stained punctuations (score &gt;= 1b);&#xD;
&#xD;
          -  Hypersensitivity to one of the products used in the study;&#xD;
&#xD;
          -  Clinically relevant allergy;&#xD;
&#xD;
          -  Medical or surgical history incompatible with the study;&#xD;
&#xD;
          -  Recent acute illness;&#xD;
&#xD;
          -  Ocular surgery, including LASIK, LASEK and PRK within the last 12 months;&#xD;
&#xD;
          -  Other ocular lasers or Zithromax® or Azadose® within the last 3 months;&#xD;
&#xD;
          -  Systemic antibiotics and ocular medications within the last month;&#xD;
&#xD;
          -  Contact lenses within the last week;&#xD;
&#xD;
          -  Any medication on Day 0 and during the study (except paracetamol and contraceptives).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude DUBRAY, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Pharmacologie Clinique - Clermont-Ferrand (France)</affiliation>
  </overall_official>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>July 25, 2006</last_update_submitted>
  <last_update_submitted_qc>July 25, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Eye Infections, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

